
Opinion|Videos|October 24, 2024
Impact of Comorbidities on IPF Management
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
- Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?
Advertisement
Related to this article

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
COPD Disease Stability Emerges as a Treatment Target in GOLD 2026
4
Patient Fit Matters Most When Choosing the Right COPD Inhaler
5



